IN165717B
(da)
*
|
1986-08-07 |
1989-12-23 |
Battelle Memorial Institute |
|
US5529932A
(en)
*
|
1988-01-28 |
1996-06-25 |
Pharmacia, S.P.A. |
Isolated DNA encoding a plant ribosome inactivating protein from the leaves of saponaria officinalis
|
IL106992A
(en)
*
|
1988-02-11 |
1994-06-24 |
Bristol Myers Squibb Co |
Noble hydrazonic history of anthracycline and methods for their preparation
|
DE4004573A1
(de)
*
|
1989-02-17 |
1990-08-23 |
Tanabe Seiyaku Co |
Neues versuchstier und seine herstellung
|
US5354844A
(en)
*
|
1989-03-16 |
1994-10-11 |
Boehringer Ingelheim International Gmbh |
Protein-polycation conjugates
|
US5191067A
(en)
*
|
1989-04-27 |
1993-03-02 |
The Salk Institute For Biological Studies |
Fibroblast growth factor conjugates
|
US5576288A
(en)
*
|
1989-04-27 |
1996-11-19 |
The Salk Institute For Biological Studies |
Fibroblast growth factor conjugates
|
IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
ES2070329T3
(es)
*
|
1989-07-20 |
1995-06-01 |
Sandoz Ltd |
Derivados de polipeptidos.
|
US5208323A
(en)
*
|
1989-08-10 |
1993-05-04 |
Universite Laval |
Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
US5182107A
(en)
*
|
1989-09-07 |
1993-01-26 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
JPH04505019A
(ja)
*
|
1989-10-23 |
1992-09-03 |
シェリング・コーポレーション |
ガンマインターフェロンのポリペプチド性阻害剤
|
DK0517829T4
(da)
*
|
1990-03-02 |
2008-03-03 |
Boston Medical Ct Corp |
Forbedrede kimæriske toksiner
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
US5137877B1
(en)
*
|
1990-05-14 |
1996-01-30 |
Bristol Myers Squibb Co |
Bifunctional linking compounds conjugates and methods for their production
|
JP2640293B2
(ja)
*
|
1990-05-30 |
1997-08-13 |
ドイチエス クレープスフオルシユングスツエントルム ステイフツング デス アフエントリヒエン レヒトス |
ポリエーテル置換抗腫瘍剤
|
IL98528A0
(en)
*
|
1990-06-21 |
1992-07-15 |
Merck & Co Inc |
Pharmaceutical compositions containing hybrid for killing bladder cancer cells
|
AU657910B2
(en)
*
|
1990-07-05 |
1995-03-30 |
Akzo N.V. |
Receptor directed-toxin conjugates
|
US5478804A
(en)
*
|
1990-09-19 |
1995-12-26 |
The Salk Institute For Biological Studies |
Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
|
EP0510132B1
(en)
*
|
1990-09-28 |
1997-05-14 |
Neorx Corporation |
Polymeric carriers for release of covalently linked agents
|
US5431899A
(en)
*
|
1991-02-04 |
1995-07-11 |
University Of Saskatchewan |
Rotavirus VP6 as a diagnostic and targeting agent
|
US5464753A
(en)
*
|
1991-03-08 |
1995-11-07 |
Univ Illinois |
Purification and manipulation of bone marrow and blood cells on the basis of P-glycoprotein expression
|
WO1992016221A1
(en)
*
|
1991-03-15 |
1992-10-01 |
Synergen, Inc. |
Pegylation of polypeptides
|
CA2102808A1
(en)
*
|
1991-05-10 |
1992-11-11 |
Hanne Bentz |
Targeted delivery of bone growth factors
|
DE69112053D1
(de)
*
|
1991-07-22 |
1995-09-14 |
Bracco Int Bv |
Anwendung von Chelaten von Konjugaten mit paramagnetischen Metallen für Targetting.
|
US5981273A
(en)
*
|
1991-09-30 |
1999-11-09 |
Boehringer Ingelheim Int'l. Gmbh |
Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
|
NZ244306A
(en)
*
|
1991-09-30 |
1995-07-26 |
Boehringer Ingelheim Int |
Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
|
US5521291A
(en)
*
|
1991-09-30 |
1996-05-28 |
Boehringer Ingelheim International, Gmbh |
Conjugates for introducing nucleic acid into higher eucaryotic cells
|
US5922859A
(en)
*
|
1992-02-01 |
1999-07-13 |
Boehringer Ingelheim International Gmbh |
Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
|
CA2076465C
(en)
*
|
1992-03-25 |
2002-11-26 |
Ravi V. J. Chari |
Cell binding agent conjugates of analogues and derivatives of cc-1065
|
US5679350A
(en)
*
|
1992-05-28 |
1997-10-21 |
The University Of Toledo |
Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material
|
EP0643584B1
(en)
*
|
1992-05-28 |
2000-03-15 |
The University Of Toledo |
Delivery of a cytotoxic compound to a cancer cell using a pathway of plasminogen activator material
|
EP0646174A1
(en)
*
|
1992-06-16 |
1995-04-05 |
The Whittier Institute For Diabetes And Endocrinology |
Recombinant production of saporin-containing proteins
|
US5393737A
(en)
*
|
1992-08-20 |
1995-02-28 |
Health Research, Inc. |
Cytotoxic drug conjugates for treatment of neoplastic diseases
|
AU5125693A
(en)
*
|
1992-09-03 |
1994-03-29 |
Regents Of The University Of California, The |
Dorsal tissue affecting factor and compositions
|
US5466672A
(en)
*
|
1992-12-04 |
1995-11-14 |
Ophidian Pharmaceuticals, Inc. |
Therapeutic use of clostridium difficile toxin A
|
ES2146649T3
(es)
|
1993-05-05 |
2000-08-16 |
Keith Rose |
Compuestos de polioximas y su preparacion.
|
US6174530B1
(en)
|
1993-05-05 |
2001-01-16 |
Gryphon Sciences |
Homogeneous polyoxime compositions and their preparation by parallel assembly
|
US6001364A
(en)
*
|
1993-05-05 |
1999-12-14 |
Gryphon Sciences |
Hetero-polyoxime compounds and their preparation by parallel assembly
|
US6214345B1
(en)
*
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
US5502037A
(en)
*
|
1993-07-09 |
1996-03-26 |
Neuromed Technologies, Inc. |
Pro-cytotoxic drug conjugates for anticancer therapy
|
US6491905B1
(en)
*
|
1993-09-14 |
2002-12-10 |
The Uab Research Foundation |
Recombinant bacterial cells for delivery of PNP to tumor cells
|
PT648503E
(pt)
*
|
1993-09-22 |
2000-11-30 |
Hoechst Ag |
Pro-profarmacos, sua producao e utilizacao
|
US5879656A
(en)
*
|
1993-10-26 |
1999-03-09 |
Thomas Jefferson University |
Methods of treating metastatic colorectal cancer with ST receptor binding compounds
|
US7097839B1
(en)
|
1993-10-26 |
2006-08-29 |
Thomas Jefferson University |
ST receptor binding compounds and methods of using the same
|
US5962220A
(en)
*
|
1993-10-26 |
1999-10-05 |
Thomas Jefferson University |
Compositions that specifically bind to colorectal cells and methods of using the same
|
CA2137639C
(en)
*
|
1993-12-09 |
1999-01-26 |
Agustin B. L. Davila |
Vaccine composition comprising autologous epidermal growth factor or a fragment or a derivate thereof having anti-tumor activity and use thereof in the therapy of malignant diseases
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
US5587459A
(en)
*
|
1994-08-19 |
1996-12-24 |
Regents Of The University Of Minnesota |
Immunoconjugates comprising tyrosine kinase inhibitors
|
US5911995A
(en)
*
|
1994-08-19 |
1999-06-15 |
Regents Of The University Of Minnesota |
EGF-genistein conjugates for the treatment of cancer
|
DE4433890C2
(de)
*
|
1994-09-22 |
1999-02-18 |
Deutsches Krebsforsch |
Konjugat aus einem Wirkstoff und einem nicht als körperfremd angesehenen, nativen Protein
|
WO1996014834A1
(en)
*
|
1994-11-10 |
1996-05-23 |
University Of Kentucky Research Foundation |
Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
|
US5766899A
(en)
*
|
1995-02-27 |
1998-06-16 |
Board Of Regents , The University Of Texas System |
Targeted nucleic acid delivery into liver cells
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US20030119724A1
(en)
*
|
1995-11-22 |
2003-06-26 |
Ts`O Paul O.P. |
Ligands to enhance cellular uptake of biomolecules
|
WO1997023243A1
(en)
*
|
1995-12-22 |
1997-07-03 |
Bristol-Myers Squibb Company |
Branched hydrazone linkers
|
US20050025740A1
(en)
*
|
1996-01-05 |
2005-02-03 |
Keith Rose |
Polyoxime compounds and their preparation
|
US6441025B2
(en)
*
|
1996-03-12 |
2002-08-27 |
Pg-Txl Company, L.P. |
Water soluble paclitaxel derivatives
|
PL189698B1
(pl)
|
1996-03-12 |
2005-09-30 |
Pg Txl Co |
Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
|
US6030941A
(en)
*
|
1996-05-01 |
2000-02-29 |
Avi Biopharma, Inc. |
Polymer composition for delivering substances in living organisms
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
US5952294A
(en)
*
|
1996-07-31 |
1999-09-14 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Peptidyl prodrugs and methods of making and using the same
|
DE19636889A1
(de)
|
1996-09-11 |
1998-03-12 |
Felix Dr Kratz |
Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
|
US6080383A
(en)
*
|
1997-01-13 |
2000-06-27 |
Rose; Samuel |
Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
|
AU7124598A
(en)
*
|
1997-04-18 |
1998-11-13 |
Access Pharmaceuticals, Inc. |
Polymer-platinum compounds
|
US5965118A
(en)
*
|
1997-04-18 |
1999-10-12 |
Access Pharmaceuticals, Inc. |
Polymer-platinum compounds
|
US6548482B1
(en)
|
1997-05-05 |
2003-04-15 |
Mayo Foundation For Medical Education And Research |
Treatment of osteoporosis
|
US6916790B2
(en)
|
1997-05-05 |
2005-07-12 |
Mayo Foundation For Medical Education And Research |
Treatment of osteoporosis
|
DE69835878T2
(de)
*
|
1997-05-05 |
2007-04-26 |
Mayo Foundation For Medical Education And Research, Rochester |
IGFIIE/ IGFBP2 Komplex
|
US6030997A
(en)
*
|
1998-01-21 |
2000-02-29 |
Eilat; Eran |
Acid labile prodrugs
|
US6866837B2
(en)
|
1998-06-05 |
2005-03-15 |
Mallinckrodt Inc. |
Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors
|
US6747055B1
(en)
|
1998-07-17 |
2004-06-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Water-soluble drugs and methods for their production
|
CA2338000C
(en)
*
|
1998-07-17 |
2009-12-15 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Water-soluble 4-thio-maleimido derivatives and methods for their production
|
GB9904582D0
(en)
*
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
US7018654B2
(en)
*
|
1999-03-05 |
2006-03-28 |
New River Pharmaceuticals Inc. |
Pharmaceutical composition containing an active agent in an amino acid copolymer structure
|
US6716452B1
(en)
*
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US7060708B2
(en)
*
|
1999-03-10 |
2006-06-13 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US20010041189A1
(en)
*
|
1999-04-13 |
2001-11-15 |
Jingya Xu |
Poly(dipeptide) as a drug carrier
|
US6706892B1
(en)
*
|
1999-09-07 |
2004-03-16 |
Conjuchem, Inc. |
Pulmonary delivery for bioconjugation
|
US20030054977A1
(en)
*
|
1999-10-12 |
2003-03-20 |
Cell Therapeutics, Inc. |
Manufacture of polyglutamate-therapeutic agent conjugates
|
US7067111B1
(en)
*
|
1999-10-25 |
2006-06-27 |
Board Of Regents, University Of Texas System |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
US20020077290A1
(en)
*
|
2000-03-17 |
2002-06-20 |
Rama Bhatt |
Polyglutamic acid-camptothecin conjugates and methods of preparation
|
CA2404432A1
(en)
|
2000-03-27 |
2001-10-04 |
Thomas Jefferson University |
Compositions and methods for identifying and targeting cancer cells
|
CN1292798C
(zh)
|
2000-06-02 |
2007-01-03 |
德克萨斯州立大学董事会 |
乙二半胱氨酸(ec)-药物缀合物
|
WO2002002147A2
(en)
*
|
2000-06-30 |
2002-01-10 |
Board Of Regents, The University Of Texas System |
Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery
|
US7163918B2
(en)
|
2000-08-22 |
2007-01-16 |
New River Pharmaceuticals Inc. |
Iodothyronine compositions
|
US20020099013A1
(en)
*
|
2000-11-14 |
2002-07-25 |
Thomas Piccariello |
Active agent delivery systems and methods for protecting and administering active agents
|
WO2002032400A1
(en)
*
|
2000-10-16 |
2002-04-25 |
Neopharm, Inc. |
Liposomal formulation of mitoxantrone
|
US8394813B2
(en)
*
|
2000-11-14 |
2013-03-12 |
Shire Llc |
Active agent delivery systems and methods for protecting and administering active agents
|
AU2002217980A1
(en)
|
2000-12-01 |
2002-06-11 |
Cell Works Inc. |
Conjugates of glycosylated/galactosylated peptide
|
CU22999A1
(es)
|
2001-12-04 |
2004-10-12 |
Centro Inmunologia Molecular |
Método de tratamiento de enfermedades malignas e infecciosas crónicas
|
EP1389090A2
(en)
*
|
2001-04-26 |
2004-02-18 |
Board of Regents, The University of Texas System |
Diagnostic imaging compositions, their methods of synthesis and use
|
PT1392359E
(pt)
|
2001-05-11 |
2010-01-27 |
Ludwig Inst For Cancer Res Ltd |
Proteínas de ligação específica e suas utilizações
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
WO2002092116A1
(en)
*
|
2001-05-15 |
2002-11-21 |
Faulk Pharmaceuticals, Inc. |
Targeted delivery of drugs for the treatment of viral infections
|
US7001991B2
(en)
*
|
2001-05-15 |
2006-02-21 |
Faulk Pharmaceuticals, Inc. |
Targeted delivery of bioaffecting compounds for the treatment of cancer
|
WO2003000711A1
(en)
*
|
2001-06-22 |
2003-01-03 |
The University Of British Columbia |
Antimitotic eleuthesides
|
WO2003072046A2
(en)
*
|
2002-02-22 |
2003-09-04 |
New River Pharmaceuticals Inc. |
Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
|
US20060014697A1
(en)
*
|
2001-08-22 |
2006-01-19 |
Travis Mickle |
Pharmaceutical compositions for prevention of overdose or abuse
|
US7375082B2
(en)
*
|
2002-02-22 |
2008-05-20 |
Shire Llc |
Abuse-resistant hydrocodone compounds
|
US20070066537A1
(en)
*
|
2002-02-22 |
2007-03-22 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US7338939B2
(en)
*
|
2003-09-30 |
2008-03-04 |
New River Pharmaceuticals Inc. |
Abuse-resistant hydrocodone compounds
|
US7169752B2
(en)
*
|
2003-09-30 |
2007-01-30 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US20030109432A1
(en)
*
|
2001-12-10 |
2003-06-12 |
Zuo William W. |
Anticancer polypeptide-metal complexes and compositions, methods of making, and methods of using same
|
US7261875B2
(en)
*
|
2001-12-21 |
2007-08-28 |
Board Of Regents, The University Of Texas System |
Dendritic poly (amino acid) carriers and methods of use
|
RU2196604C1
(ru)
*
|
2001-12-21 |
2003-01-20 |
Северин Евгений Сергеевич |
Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
|
US7659253B2
(en)
*
|
2002-02-22 |
2010-02-09 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
US7105486B2
(en)
*
|
2002-02-22 |
2006-09-12 |
New River Pharmaceuticals Inc. |
Abuse-resistant amphetamine compounds
|
EP2316468A1
(en)
|
2002-02-22 |
2011-05-04 |
Shire LLC |
Delivery system and methods for protecting and administering dextroamphetamine
|
EP1481078A4
(en)
*
|
2002-02-22 |
2006-08-16 |
New River Pharmaceuticals Inc |
USE OF A PEPTIDE DRUG CONJUGATION TO REDUCE VARIABILITY OF MEDICAMENT SERUM MIRRORS BETWEEN PATIENTS
|
US7700561B2
(en)
*
|
2002-02-22 |
2010-04-20 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
EP2422775A3
(en)
|
2002-09-20 |
2012-04-18 |
Alpharma, Inc. |
Sequestering subunit and related compositions and methods
|
CN1723042B
(zh)
*
|
2002-11-07 |
2010-12-01 |
得克萨斯大学体系董事会 |
乙二半胱氨酸(ec)-药物结合物、组合物及用于组织特异性疾病显像的方法
|
WO2005001889A2
(en)
|
2003-05-07 |
2005-01-06 |
Indiana University Research & Technology Corporation |
Alloyed semiconductor quantum dots and concentration-gradient alloyed quantum dots, series comprising the same and methods related thereto
|
NZ544162A
(en)
*
|
2003-05-29 |
2008-09-26 |
Shire Llc |
Abuse resistant amphetamine compounds
|
US20070087959A1
(en)
*
|
2003-08-19 |
2007-04-19 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Method of inducing biomineralization method of inducing bone regeneration and methods related thereof
|
MXPA06003619A
(es)
*
|
2003-09-30 |
2008-01-14 |
New River Pharmaceuticals Inc |
Composiciones farmaceuticas para prevencion de sobredosis o abuso.
|
EP1675857B1
(en)
|
2003-10-22 |
2011-07-13 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
|
WO2005055931A2
(en)
|
2003-12-03 |
2005-06-23 |
University Of Medicine And Dentistry Of New Jersey |
Method of preventing survival of retrovirally cells and of inhibiting formation of infectious retroviruses
|
US9050378B2
(en)
*
|
2003-12-10 |
2015-06-09 |
Board Of Regents, The University Of Texas System |
N2S2 chelate-targeting ligand conjugates
|
DE602004025612D1
(de)
*
|
2003-12-10 |
2010-04-01 |
Toudai Tlo Ltd |
Koordinationskomplex von diaminocyclohexanplatin(ii) mit einem blockcopolymer mit einem poly(carbonsäure)segment und diesen enthaltendes antitumormittel
|
SI1732949T1
(sl)
|
2004-04-07 |
2010-05-31 |
Rinat Neuroscience Corp |
Postopki za zdravljenje bolečine kostnega raka zdajanjem antagonista živčnega rastnega faktorja
|
US20060036084A1
(en)
*
|
2004-08-04 |
2006-02-16 |
Lianhua Qu |
Conglomerated semiconductor nanocrystals
|
US8454927B2
(en)
*
|
2004-08-04 |
2013-06-04 |
Crystalplex Corporation |
Alloyed semiconductor nanocrystals
|
JP5201572B2
(ja)
*
|
2005-06-09 |
2013-06-05 |
ナノキャリア株式会社 |
白金錯体のポリマー化配位化合物の製造方法
|
US7867977B2
(en)
*
|
2005-11-03 |
2011-01-11 |
The United States Of America As Represented By The Department Of Health And Human Services |
Immunogenic peptides and methods of use for treating and preventing cancer
|
ATE432955T1
(de)
*
|
2005-12-05 |
2009-06-15 |
Nitto Denko Corp |
Polyglutamat-aminosäure-konjugate und verfahren
|
US7820174B2
(en)
|
2006-02-24 |
2010-10-26 |
The United States Of America As Represented By The Department Of Health And Human Services |
T cell receptors and related materials and methods of use
|
US9107863B2
(en)
|
2006-03-27 |
2015-08-18 |
The Buck Institute For Age Reasearch |
Reagents and methods for cancer treatment and prevention
|
US8758723B2
(en)
|
2006-04-19 |
2014-06-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for cellular imaging and therapy
|
CA2655835C
(en)
|
2006-06-19 |
2015-07-21 |
Alpharma, Inc. |
Abuse-resistant pharmaceutical compositions of opioid agonists
|
US8088379B2
(en)
|
2006-09-26 |
2012-01-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Modified T cell receptors and related materials and methods
|
US10925977B2
(en)
*
|
2006-10-05 |
2021-02-23 |
Ceil>Point, LLC |
Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
|
JP5399255B2
(ja)
|
2006-10-31 |
2014-01-29 |
アメリカ合衆国 |
スムースンドポリペプチドおよび使用方法
|
CA2674445C
(en)
|
2007-01-12 |
2016-06-07 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Gp100-specific t cell receptors and related materials and methods of use
|
EP2126127B1
(en)
*
|
2007-01-25 |
2016-09-28 |
Dana-Farber Cancer Institute, Inc. |
Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
|
US20080181852A1
(en)
*
|
2007-01-29 |
2008-07-31 |
Nitto Denko Corporation |
Multi-functional Drug Carriers
|
AU2008227123B2
(en)
|
2007-03-15 |
2014-03-27 |
Ludwig Institute For Cancer Research Ltd. |
Treatment method using EGFR antibodies and src inhibitors and related formulations
|
WO2008124735A2
(en)
*
|
2007-04-10 |
2008-10-16 |
Nitto Denko Corporation |
Multi-functional polyglutamate drug carriers
|
EP2155254B1
(en)
*
|
2007-05-09 |
2012-11-28 |
Nitto Denko Corporation |
Polymers conjugated with platinum drugs
|
CN101707869A
(zh)
*
|
2007-05-09 |
2010-05-12 |
日东电工株式会社 |
具有多种药物的聚谷氨酸盐结合物和聚谷氨酸盐-氨基酸结合物
|
DK2155255T3
(da)
|
2007-05-09 |
2013-09-02 |
Nitto Denko Corp |
Sammensætninger der omfatter en hydrofob forbindelse og et polyaminosyrekonjugat
|
CN101896503B
(zh)
|
2007-08-14 |
2018-05-22 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
EP2188296A1
(en)
*
|
2007-08-31 |
2010-05-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compounds for inhibiting wip1, prodrugs and compositions thereof, and related methods
|
RU2010137032A
(ru)
*
|
2008-03-06 |
2012-04-20 |
Нитто Денко Корпорейшн (Jp) |
Конъюгаты паклитаксела с полимером и способы лечения рака
|
WO2010075417A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Survivin specific t cell receptor for treating cancer
|
WO2010075303A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
|
US8785601B2
(en)
|
2009-01-28 |
2014-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell receptors and related materials and methods of use
|
US9616245B2
(en)
*
|
2009-03-16 |
2017-04-11 |
Rajah Vijay Kumar |
Method of treating cells with drug and radiation according to proton density
|
US8563513B2
(en)
|
2009-03-27 |
2013-10-22 |
Van Andel Research Institute |
Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
|
US9849146B2
(en)
|
2009-07-20 |
2017-12-26 |
Rutgers, The State University Of New Jersey |
Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
|
US8603814B2
(en)
*
|
2009-07-20 |
2013-12-10 |
Rutgers The State University Of New Jersey |
Method of inhibiting nonsense-mediated mRNA decay
|
WO2011032099A1
(en)
|
2009-09-11 |
2011-03-17 |
The Board Of Trustees Of The University Of Illinois |
Methods of treating diastolic dysfunction and related conditions
|
US20110076232A1
(en)
*
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
CA2776143A1
(en)
|
2009-10-01 |
2011-04-07 |
The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services |
Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
|
CA2777628C
(en)
|
2009-10-16 |
2019-12-03 |
The University Of British Columbia |
Inhibitors of phosphatase and tensin homolog (pten) compositions, uses and methods
|
WO2011056572A1
(en)
|
2009-10-27 |
2011-05-12 |
The Board Of Trustees Of The University Of Illinois |
Methods of diagnosing diastolic dysfunction
|
WO2011060218A1
(en)
|
2009-11-13 |
2011-05-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modulated programmed death ligand-1
|
WO2011075393A2
(en)
|
2009-12-18 |
2011-06-23 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
US8551946B2
(en)
|
2010-01-27 |
2013-10-08 |
Indiana University Research And Technology Corporation |
Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
|
WO2011116026A2
(en)
|
2010-03-15 |
2011-09-22 |
The Board Of Trustees Of The University Of Illinois |
Inhibitors of beta integrin-g protein alpha subunit binding interactions
|
JP6133209B2
(ja)
|
2010-09-21 |
2017-05-24 |
アメリカ合衆国 |
抗ssx−2t細胞受容体及び関連材料並びに使用方法
|
WO2012054825A1
(en)
|
2010-10-22 |
2012-04-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mage-a3 t cell receptors and related materials and methods of use
|
EP2655401B1
(en)
|
2010-12-20 |
2016-03-09 |
The Regents of the University of Michigan |
Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
|
ES2713952T3
(es)
|
2010-12-22 |
2019-05-24 |
Univ Indiana Res & Tech Corp |
Análogos de glucagón que muestran actividad de receptor de GIP
|
CN102675422B
(zh)
|
2011-03-15 |
2014-02-05 |
天津托普泰克生物科技有限公司 |
抗乙型肝炎病毒x蛋白多肽药物
|
EP2694549B1
(en)
|
2011-04-08 |
2018-08-15 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
|
CN102746378B
(zh)
|
2011-04-22 |
2014-10-22 |
天津托普泰克生物科技有限公司 |
抗脂肪酸合成酶多肽及其应用
|
AU2012268013B2
(en)
|
2011-06-09 |
2016-11-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes
|
GEP20176629B
(en)
|
2011-06-22 |
2017-02-27 |
Indiana Unversity Research And Tech Corporation |
Glucagon/glp-1 receptor co-agonists
|
CN103974974A
(zh)
|
2011-09-15 |
2014-08-06 |
美国卫生和人力服务部 |
识别hla-a1-或hla-cw7-限制的mage的t细胞受体
|
WO2013040141A1
(en)
|
2011-09-16 |
2013-03-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Pseudomonas exotoxin a with less immunogenic b cell epitopes
|
AU2012325915A1
(en)
|
2011-10-20 |
2014-04-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD22 chimeric antigen receptors
|
KR20140097151A
(ko)
|
2011-11-17 |
2014-08-06 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
|
US9359447B2
(en)
|
2012-03-23 |
2016-06-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
RU2766608C2
(ru)
|
2012-04-11 |
2022-03-15 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
|
EP3527584B8
(en)
|
2012-05-22 |
2020-12-16 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Medical use of cells comprising anti-ny-eso-1 t cell receptors
|
WO2013188740A1
(en)
|
2012-06-14 |
2013-12-19 |
Ambrx, Inc. |
Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
|
TR201808818T4
(tr)
|
2012-06-21 |
2018-07-23 |
Novo Nordisk As |
Gip reseptör aktivitesi sergileyen glukagon analogları.
|
TWI599575B
(zh)
|
2012-06-21 |
2017-09-21 |
印第安納大學科技研究公司 |
表現gip受體活性之胰高血糖素類似物
|
ES2925307T3
(es)
|
2012-09-14 |
2022-10-14 |
Us Health |
Receptores de linfocitos T que reconocen MAGE-A3 restringida al MHC de clase II
|
CN110229834B
(zh)
|
2012-10-24 |
2022-11-01 |
美国卫生和人力服务部 |
M971嵌合抗原受体
|
US9790282B2
(en)
|
2013-03-25 |
2017-10-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
|
US9890369B2
(en)
|
2013-06-20 |
2018-02-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor
|
EP3572423B1
(en)
|
2013-07-15 |
2023-12-06 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Anti-human papillomavirus 16 e6 t cell receptors
|
CA2926215A1
(en)
|
2013-10-06 |
2015-04-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modified pseudomonas exotoxin a
|
CA2932424C
(en)
|
2013-12-06 |
2023-10-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
|
BR112016024579A2
(pt)
|
2014-04-23 |
2017-10-10 |
Juno Therapeutics Inc |
métodos para isolamento, cultura e engenharia genética de populações de célula imune para terapia adotiva
|
LT3149031T
(lt)
|
2014-05-29 |
2020-05-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T ląstelių receptoriai prieš žmogaus papilomos virusą 16 e7
|
CN106536564B
(zh)
|
2014-06-02 |
2021-08-31 |
美国卫生和人力服务部 |
靶向cd-19的嵌合抗原受体
|
MA40253A
(fr)
|
2014-07-15 |
2017-05-24 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
KR20170068598A
(ko)
|
2014-10-20 |
2017-06-19 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 치료에서 복용을 위한 방법 및 조성물
|
EP3215164A1
(en)
|
2014-11-03 |
2017-09-13 |
Immures S.r.l. |
T cell receptors
|
RS60685B1
(sr)
|
2014-11-05 |
2020-09-30 |
Juno Therapeutics Inc |
Postupci za transdukciju i obradu ćelija
|
MX2017007138A
(es)
|
2014-12-03 |
2017-08-28 |
Juno Therapeutics Inc |
Metodos y composiciones para terapia celular adoptiva.
|
EP3245231B1
(en)
|
2015-01-16 |
2020-08-12 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
JP6949728B2
(ja)
|
2015-05-29 |
2021-10-13 |
ジュノー セラピューティクス インコーポレイテッド |
遺伝子操作された細胞における阻害相互作用を調節するための組成物および方法
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
WO2017068419A2
(en)
|
2015-10-22 |
2017-04-27 |
Juno Therapeutics Gmbh |
Methods, kits, agents and apparatuses for transduction
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
WO2017079703A1
(en)
|
2015-11-05 |
2017-05-11 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
MA44314A
(fr)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
|
CA3007262A1
(en)
|
2015-12-03 |
2017-06-08 |
Lucas James Thompson |
Modified chimeric receptors and related compositions and methods
|
ES2901795T3
(es)
|
2015-12-04 |
2022-03-23 |
Juno Therapeutics Inc |
Métodos y composiciones relacionadas con la toxicidad asociada con la terapia celular
|
WO2017161208A1
(en)
|
2016-03-16 |
2017-09-21 |
Juno Therapeutics, Inc. |
Methods for determining dosing of a therapeutic agent and related treatments
|
MA43759A
(fr)
|
2016-03-16 |
2018-11-28 |
Jason Connor |
Procédés de conception adaptative d'un régime de traitement et traitements associés
|
WO2017165571A1
(en)
|
2016-03-22 |
2017-09-28 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Early intervention methods to prevent or ameliorate toxicity
|
CN116850305A
(zh)
|
2016-05-06 |
2023-10-10 |
朱诺治疗学股份有限公司 |
基因工程化细胞及其制备方法
|
JP2019517518A
(ja)
|
2016-06-03 |
2019-06-24 |
メモリアル スローン ケタリング キャンサー センター |
早期治療選択肢としての養子細胞療法
|
MA45341A
(fr)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
|
EP3475446A1
(en)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
US20190201414A1
(en)
|
2016-07-01 |
2019-07-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv |
Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
|
ES2951552T3
(es)
|
2016-07-29 |
2023-10-23 |
Juno Therapeutics Inc |
Polipéptidos inmunomoduladores y composiciones y métodos relacionados
|
CN110139873A
(zh)
|
2016-10-03 |
2019-08-16 |
朱诺治疗学股份有限公司 |
Hpv特异性结合分子
|
US11793833B2
(en)
|
2016-12-02 |
2023-10-24 |
Juno Therapeutics, Inc. |
Engineered B cells and related compositions and methods
|
WO2018102787A1
(en)
|
2016-12-03 |
2018-06-07 |
Juno Therapeutics, Inc. |
Methods for determining car-t cells dosing
|
BR112019011025A2
(pt)
|
2016-12-03 |
2019-10-08 |
Juno Therapeutics Inc |
métodos para modulação de células t car
|
MA46998A
(fr)
|
2016-12-05 |
2019-10-09 |
Juno Therapeutics Inc |
Production de cellules modifiées pour une thérapie cellulaire adoptive
|
WO2018132518A1
(en)
|
2017-01-10 |
2018-07-19 |
Juno Therapeutics, Inc. |
Epigenetic analysis of cell therapy and related methods
|
MA47325A
(fr)
|
2017-01-20 |
2019-11-27 |
Juno Therapeutics Gmbh |
Conjugués de surface cellulaire et compositions cellulaires et méthodes associées
|
JP7178355B2
(ja)
|
2017-02-28 |
2022-11-25 |
エンドサイト・インコーポレイテッド |
Car t細胞療法のための組成物および方法
|
CA3056261A1
(en)
|
2017-04-07 |
2018-10-11 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
CN111032850A
(zh)
|
2017-04-27 |
2020-04-17 |
朱诺治疗学有限公司 |
寡聚粒子试剂及其使用方法
|
EP3631468A1
(en)
|
2017-06-02 |
2020-04-08 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods related to toxicity associated with cell therapy
|
US11413310B2
(en)
|
2017-06-02 |
2022-08-16 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
CN109517820B
(zh)
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
一种靶向HPK1的gRNA以及HPK1基因编辑方法
|
KR20200104284A
(ko)
|
2017-10-03 |
2020-09-03 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Hpv-특이적 결합 분자
|
MA50860A
(fr)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics Inc |
Récepterus chimériques d'antigène contre l'antigène de maturation des cellules b et polynucleotides codants
|
MA49911A
(fr)
|
2017-11-01 |
2020-06-24 |
Juno Therapeutics Inc |
Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
|
MX2020004239A
(es)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics Inc |
Proceso para producir una composicion de celulas t.
|
CA3081456A1
(en)
|
2017-11-01 |
2019-05-09 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
|
MA50855A
(fr)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics Inc |
Procédé de génération de compositions thérapeutiques de cellules modifiées
|
JP2021502077A
(ja)
|
2017-11-06 |
2021-01-28 |
エディタス・メディシン,インコーポレイテッド |
免疫療法のためのt細胞におけるcblbのcrispr−cas9編集のための方法、組成物および構成要素
|
MA51210A
(fr)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics Inc |
Procédés de dosage et de modulation de cellules génétiquement modifiées
|
EP3720949A1
(en)
|
2017-12-08 |
2020-10-14 |
Juno Therapeutics, Inc. |
Serum-free media formulation for culturing cells and methods of use thereof
|
US20200384025A1
(en)
|
2017-12-08 |
2020-12-10 |
Juno Therapeutics, Inc. |
Process for producing a composition of engineered t cells
|
AU2018379094A1
(en)
|
2017-12-08 |
2020-06-25 |
Juno Therapeutics, Inc. |
Phenotypic markers for cell therapy and related methods
|
US12006356B2
(en)
|
2017-12-15 |
2024-06-11 |
Juno Therapeutics, Inc. |
Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same
|
TW201940182A
(zh)
|
2018-01-22 |
2019-10-16 |
美商安德賽特公司 |
Car t 細胞之使用方法
|
US20210069246A1
(en)
|
2018-01-31 |
2021-03-11 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
US20210046159A1
(en)
|
2018-03-09 |
2021-02-18 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
BR112020020245A2
(pt)
|
2018-04-05 |
2021-04-06 |
Editas Medicine, Inc. |
Métodos de produzir células expressando um receptor recombinante e composições relacionadas
|
RU2020136054A
(ru)
|
2018-04-05 |
2022-05-06 |
Джуно Терапьютикс, Инк. |
Т-клетки, экспрессирующие рекомбинантный рецептор, соответствующие полинуклеотиды и способы
|
CN112566698A
(zh)
|
2018-04-05 |
2021-03-26 |
朱诺治疗学股份有限公司 |
T细胞受体和表达该t细胞受体的工程化细胞
|
EP3833759A1
(en)
|
2018-08-09 |
2021-06-16 |
Juno Therapeutics, Inc. |
Methods for assessing integrated nucleic acids
|
US20210163893A1
(en)
|
2018-08-09 |
2021-06-03 |
Juno Therapeutics, Inc. |
Processes for generating engineered cells and compositions thereof
|
CA3110905A1
(en)
|
2018-08-31 |
2020-03-05 |
Invectys SA |
Chimeric antigen receptors against multiple hla-g isoforms
|
US20220002669A1
(en)
|
2018-10-31 |
2022-01-06 |
Juno Therapeutics Gmbh |
Methods for selection and stimulation of cells and apparatus for same
|
KR20210113169A
(ko)
|
2018-11-01 |
2021-09-15 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법
|
MX2021005022A
(es)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics Inc |
Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
|
ES2968737T3
(es)
|
2018-11-06 |
2024-05-13 |
Juno Therapeutics Inc |
Proceso para producir células T manipuladas genéticamente
|
BR112021009420A2
(pt)
|
2018-11-16 |
2021-11-23 |
Juno Therapeutics Inc |
Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b
|
EP3886894B1
(en)
|
2018-11-30 |
2024-03-13 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
|
US20220088070A1
(en)
|
2018-11-30 |
2022-03-24 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
EP3917570A1
(en)
|
2019-01-29 |
2021-12-08 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
WO2020210719A1
(en)
|
2019-04-10 |
2020-10-15 |
Elevatebio Management, Inc. |
Flt3-specific chimeric antigen receptors and methods of using the same
|
MX2021013219A
(es)
|
2019-05-01 |
2022-02-17 |
Juno Therapeutics Inc |
Celulas que expresan un receptor recombinante de un locus de tgfbr2 modificado, polinucleotidos relacionados y metodos.
|
CA3136742A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
KR20220027855A
(ko)
|
2019-05-22 |
2022-03-08 |
매사추세츠 인스티튜트 오브 테크놀로지 |
원형 rna 조성물 및 방법
|
CN112390894A
(zh)
|
2019-08-12 |
2021-02-23 |
广东东阳光药业有限公司 |
嵌合抗原受体及其应用
|
JP2023500318A
(ja)
|
2019-10-30 |
2023-01-05 |
ジュノ セラピューティクス ゲーエムベーハー |
細胞選択および/または細胞刺激デバイスならびに使用方法
|
MX2022006715A
(es)
|
2019-12-06 |
2022-09-23 |
Juno Therapeutics Inc |
Metodos relacionados con toxicidad y respuesta asociada con terapia celular para tratar neoplasias malignas de celulas b.
|
US20230090117A1
(en)
|
2020-01-28 |
2023-03-23 |
Juno Therapeutics, Inc. |
Methods for t cell transduction
|
US20230149462A1
(en)
|
2020-04-10 |
2023-05-18 |
Juno Therapeutics, Inc. |
Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
|
JP2023528215A
(ja)
|
2020-05-13 |
2023-07-04 |
ジュノー セラピューティクス インコーポレイテッド |
臨床応答に関連する特徴量の特定方法およびその使用
|
BR112022023554A2
(pt)
|
2020-05-19 |
2023-04-11 |
Orna Therapeutics Inc |
Composições e métodos de rna circular
|
US20240216508A1
(en)
|
2020-06-26 |
2024-07-04 |
Juno Therapeutics Gmbh |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
US20230398148A1
(en)
|
2020-11-04 |
2023-12-14 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
CA3210581A1
(en)
|
2021-03-22 |
2022-09-29 |
Neil HAIG |
Methods of determining potency of a therapeutic cell composition
|
CN117916256A
(zh)
|
2021-05-06 |
2024-04-19 |
朱诺治疗学有限公司 |
用于刺激和转导t细胞的方法
|
CN115404240A
(zh)
|
2021-05-28 |
2022-11-29 |
上海环码生物医药有限公司 |
制备环形rna的构建体、方法及其用途
|
WO2023081735A1
(en)
|
2021-11-03 |
2023-05-11 |
Celgene Corporation |
Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
|
CA3236235A1
(en)
|
2021-11-08 |
2023-05-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
WO2023164440A1
(en)
|
2022-02-22 |
2023-08-31 |
Juno Therapeutics, Inc. |
Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
WO2023231959A2
(en)
|
2022-05-30 |
2023-12-07 |
Shanghai Circode Biomed Co., Ltd |
Synthetic circular rna compositions and methods of use thereof
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
WO2024031091A2
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
WO2024129778A2
(en)
|
2022-12-13 |
2024-06-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
|
WO2024129982A2
(en)
|
2022-12-15 |
2024-06-20 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|